NASDAQ:BBOT BridgeBio Oncology Therapeutics Q3 2026 Earnings Results & Report $2.20 -0.10 (-4.35%) Closing price 04:00 PM EasternExtended Trading$2.29 +0.09 (+3.91%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BridgeBio Oncology Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.43 versus the -$0.65 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call4:00 PM ET BridgeBio Oncology Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.65Beat/MissBeat by +$0.22One Year Ago EPSN/ABridgeBio Oncology Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) BridgeBio Oncology Therapeutics Q3 2026 Earnings FAQ Did BridgeBio Oncology Therapeutics beat earnings estimates for Q3 2026? BridgeBio Oncology Therapeutics (NASDAQ:BBOT) reported earnings of -$0.43 per share for Q3 2026, beating the consensus estimate of -$0.65. The report was announced on Tuesday, November 10, 2026. BridgeBio Oncology Therapeutics Earnings HeadlinesBBOT Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNovember 10 at 4:15 PM | globenewswire.comBridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsNovember 2, 2026 | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Piper Sandler Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)October 27, 2026 | theglobeandmail.comBridgeBio Oncology: The KRAS Opportunity Hidden In The SelloffOctober 19, 2026 | seekingalpha.comBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 12, 2026 | globenewswire.comSee More BridgeBio Oncology Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Oncology Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Oncology Therapeutics and other key companies, straight to your email. Email Address About BridgeBio Oncology TherapeuticsBridgeBio Oncology Therapeutics (NASDAQ:BBOT). is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets. Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat. BridgeBio Oncology Therapeutics is advancing its pipeline through preclinical research and clinical development, with the goal of providing targeted treatment options for patients with limited alternatives. The company’s operations are focused on drug discovery and development rather than commercialized products, and its therapies remain subject to clinical testing and regulatory review. Information about its specific commercial reach and leadership is limited; the company’s principal activities are conducted through its oncology research and development programs.View BridgeBio Oncology Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
